Measurements on biological fluids form the mainstay of routine clinical investigations. Samples of blood, urine, etc are, generally, easily obtainable and measurements can be interpreted directly. On ...
Additional orphan designation reinforces Sanofi’s commitment to developing treatments for rare diseases Efdoralprin alfa, an investigational restorative recombinant therapy, recently met all primary ...
Objective: Severe Pi*ZZ alpha-1 antitrypsin (AAT) deficiency, caused by the Glu342Lys mutation in the SERPINA1 gene, resulting in protein misfolding and polymerization in hepatocytes, and proteotoxic ...
Chronic obstructive pulmonary disease (COPD) remains highly prevalent among veterans, but the contribution of alpha-1 antitrypsin deficiency (AAT deficiency or AATD) to this patient population remains ...
MOLINE, Ill. — November is Alpha-1 Awareness Month, a time dedicated to increasing understanding of Alpha-1 Antitrypsin Deficiency, a rare genetic condition that can cause serious lung and liver ...
November is Alpha-1 Awareness Month, a genetic condition that can lead to serious lung and liver disease. Right now, there is no cure and it is often undiagnosed. Democrats Release New Epstein Emails ...
Sanofi’s efdoralprin alfa met all primary and key secondary endpoints in alpha-1 antitrypsin deficiency emphysema phase 2 study Efdoralprin alfa demonstrated superiority in a head-to-head study versus ...
French pharmaceutical company Sanofi said Wednesday an experimental drug it acquired in a buyout last year succeeded in a mid-stage trial against a rare liver and lung disease. According to Sanofi, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results